Authors:
R Baird, RN van Zyl-Smit, A Iveson, J Duddy, SMB Rassam
Journal name: 
Leuk Lymphoma
Citation info: 
45(1):179-181
Abstract: 
We report a case of secondary acute myeloid leukaemia (AML) following high dose therapy for diffuse large B-cell non-Hodgkin's lymphoma (NHL) who developed meningeal leukaemia. This was refractory to systemic and intrathecal chemotherapy and cranial irradiation. Thalidomide has been reported to have anti-AML activity and appears to cross the blood brain barrier (BBB). We, therefore, attempted a trial of oral Thalidomide and achieved rapid biochemical and cytological remission with a short course. The patient, however, progressed systemically and succumbed to her illness.
DOI: 
http://doi.org/10.1080/1042819031000149412
E-pub date: 
01 Jan 2004
Users with this publication listed: 
Richard Baird